Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy, safety and immunogenicity of GX-19N in healthy individuals who have received one of COVID-19 vaccine authorized for emergency use.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05067946
Study type Interventional
Source Genexine, Inc.
Contact Minkyu Heo
Phone 82-31-628-3340
Email [email protected]
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date October 2021
Completion date October 2023

See also
  Status Clinical Trial Phase
Recruiting NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Not yet recruiting NCT04999098 - Clinical Study to Assess the Antiviral Properties of Echinaforce Reducing Oropharyngeal Concentration and Infectivity of SARS-CoV2 Phase 4
Not yet recruiting NCT04978038 - Third Dose of COVID-19 Vaccine in LTCF Residents Phase 4
Active, not recruiting NCT05055505 - The School SPIT Study - Elementary Schools in Low COVID-19 Incidence Regions N/A
Active, not recruiting NCT05055492 - The School SPIT Study - Elementary Schools in High COVID-19 Incidence Regions N/A
Active, not recruiting NCT05060510 - The School SPIT Study - COVID-19 Testing in Secondary Schools N/A
Recruiting NCT05054218 - COVID-19 Immunogenicity of a Third Dose of mRNA-1273 Vaccine Among Cancer Patients
Recruiting NCT05076253 - Efficacy of Ivermectin in COVID-19 Phase 1/Phase 2
Not yet recruiting NCT04528771 - S-Nitrosylation Therapy of COVID-19 Phase 1
Not yet recruiting NCT05030974 - RECOVAC Booster Vaccination Study Phase 4
Not yet recruiting NCT05077969 - Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients (Addendum 2) Phase 2
Not yet recruiting NCT05013034 - Exploratory Regimen of Basiliximab for Treatment of Pulmonary Cytokine Storm in SARS-CoV-2 Hospitalized Adult Patients Phase 2
Not yet recruiting NCT05073718 - Acetylsalicylic Acid in COVID-19 (ASA-SARS) Phase 3
Not yet recruiting NCT05047783 - Masitinib in Patients With Symptomatic Mild to Moderate COVID-19 Phase 2
Not yet recruiting NCT04590222 - Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19
Recruiting NCT04953039 - Use of Saliva for COVID-19 Diagnosis
Not yet recruiting NCT05074121 - NAC for Attenuation of COVID Symptomatology Phase 2
Recruiting NCT04918797 - COVAXIN in a Pediatric Cohort Phase 2/Phase 3
Completed NCT04893694 - the Prevalence of Oral Manifestation in Patients With SARS-CoV2 Infection
Recruiting NCT04883190 - Fatigue a Long COVID-19 Symptom Substudy of FSC19-KN Trial